We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
-2.15%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$574M
AUM Growth
-$338M
Cap. Flow
-$522M
Cap. Flow %
-91.01%
Top 10 Hldgs %
44.83%
Holding
163
New
26
Increased
13
Reduced
41
Closed
50

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$12.3M
2
AMGN icon
Amgen
AMGN
+$11.3M
3
SLN
Silence Therapeutics
SLN
+$10.8M
4
VKTX icon
Viking Therapeutics
VKTX
+$9.06M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$6.59M

Top Sells

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$10.5M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$10.4M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.14M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$7.96M
5
ANNX icon
Annexon
ANNX
+$5.3M

Sector Composition

Rank Sector Weight
1 Healthcare 55.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CORT icon
126
PUT
Corcept Therapeutics
CORT
$9.98B
– –
-994,500
Closed -$25.1M
CRNX icon
127
CALL
Crinetics Pharmaceuticals
CRNX
$8.88B
– –
-8,700
Closed -$407K
CRNX icon
128
PUT
Crinetics Pharmaceuticals
CRNX
$8.88B
– –
-300,400
Closed -$14.1M
CYTK icon
129
PUT
Cytokinetics
CYTK
$10.6B
– –
-100,000
Closed -$7.01M
EYPT icon
130
CALL
EyePoint Inc
EYPT
$999M
– –
-206,500
Closed -$4.27M
EYPT icon
131
EyePoint Inc
EYPT
$999M
– –
-1,047
Closed -$21.6K
EYPT icon
132
PUT
EyePoint Inc
EYPT
$999M
– –
-658,200
Closed -$13.6M
FDMT icon
133
CALL
4D Molecular Therapeutics
FDMT
$502M
– –
-257,600
Closed -$8.21M
FDMT icon
134
PUT
4D Molecular Therapeutics
FDMT
$502M
– –
-257,600
Closed -$8.21M
CBIO
135
CALL
Crescent Biopharma
CBIO
$546M
– –
-1,728
Closed -$518K
CBIO
136
PUT
Crescent Biopharma
CBIO
$546M
– –
-1,728
Closed -$518K
HOOK
137
DELISTED
HOOKIPA Pharma
HOOK
– –
-53,078
Closed -$378K
IRON icon
138
CALL
Disc Medicine
IRON
$2.81B
– –
-49,600
Closed -$3.09M
IRON icon
139
Disc Medicine
IRON
$2.81B
– –
-25,372
Closed -$1.58M
IRON icon
140
PUT
Disc Medicine
IRON
$2.81B
– –
-396,600
Closed -$24.7M
KRYS icon
141
CALL
Krystal Biotech
KRYS
$10.7B
– –
-100,000
Closed -$17.8M
KRYS icon
142
PUT
Krystal Biotech
KRYS
$10.7B
– –
-375,000
Closed -$66.7M
LNTH icon
143
CALL
Lantheus
LNTH
$6.51B
– –
-170,000
Closed -$10.6M
MDGL icon
144
PUT
Madrigal Pharmaceuticals
MDGL
$12.6B
– –
-51,400
Closed -$13.7M
MGNX icon
145
CALL
MacroGenics
MGNX
$233M
– –
-523,500
Closed -$7.71M
MLTX icon
146
PUT
MoonLake Immunotherapeutics
MLTX
$1.56B
– –
-158,000
Closed -$7.94M
PRAX icon
147
Praxis Precision Medicines
PRAX
$8.11B
– –
-168,388
Closed -$7.96M
QURE icon
148
uniQure
QURE
$2.78B
– –
-469,133
Closed -$2.44M
RAPT
149
PUT
DELISTED
RAPT Therapeutics
RAPT
– –
-30,775
Closed -$2.21M
SLNO
150
CALL
DELISTED
Soleno Therapeutics
SLNO
– –
-81,100
Closed -$3.47M
3 4 5
6
7

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Ikarian Capital held 163 positions worth $574M, down 37% from $912M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Ikarian Capital withdrew a net $522M in Q2 2024, closing 50 positions and reducing 41 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $10.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 40% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Enliven Therapeutics worth $13.7M.

  • Ikarian Capital's largest Q2 2024 buy was Enliven Therapeutics: 586,552 shares worth $13.7M.
  • Ikarian Capital added most to Sarepta Therapeutics in Q2 2024, an estimated $6.59M increase.
  • Ikarian Capital's biggest Q2 2024 reduction was Corbus Pharmaceuticals, cutting an estimated $10.5M.
  • Ikarian Capital fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $10.4M.
  • Ikarian Capital's ten largest holdings make up 45% of its $574M portfolio in Q2 2024.
  • Ikarian Capital opened 26 new positions and closed 50 in Q2 2024.
  • Ikarian Capital's portfolio value fell 37% quarter-over-quarter to $574M.

Based on Ikarian Capital's 13F filing for Q2 2024, filed 14 Aug 2024.